Survival outcomes improved in contemporary cohort of patients with pelvic or abdominal recurrence after treatment for Stage I/II endometrial carcinoma
Identifieur interne : 001791 ( Main/Exploration ); précédent : 001790; suivant : 001792Survival outcomes improved in contemporary cohort of patients with pelvic or abdominal recurrence after treatment for Stage I/II endometrial carcinoma
Auteurs : Melody J. Xu [États-Unis] ; Christina Chu [États-Unis] ; Stephen Rubin [États-Unis] ; Lilie L. Lin [États-Unis]Source :
- American journal of clinical oncology [ 0277-3732 ] ; 2015.
Abstract
Pelvic and abdominal recurrences in Stage I/II endometrial carcinoma are associated with poor outcomes, yet prognostic factors for survival after recurrence are not well-described. Herein we identify patients with pelvic or abdominal recurrence after surgery for Stage I/II endometrial carcinoma and describe symptoms at presentation, prognostic factors, and salvage treatment toxicity.
This is a retrospective cohort of 20 consecutively treated patients with recurrence after treatment for Stage I/II endometrial carcinoma followed by our Institution’s Radiation Oncology Department from 1998-2015.
The median time to pelvic or abdominal recurrence was 18.1 months (range, 4.2-59.6 months), with 50% of recurrences at extra-nodal locations. Two year progression-free survival (PFS) was 44% and 2 year overall survival (OS) was 82%. Salvage treatments varied widely, including chemotherapy and radiation therapy (RT) (7), surgery and RT (3), and surgery, chemotherapy, and RT (3). On univariate analysis of PFS, symptoms at recurrence (p=0.04) and extra-nodal recurrences (p<0.01) were found to be statistically significant negative prognosticators for PFS. On univariate analysis of OS, increasing age at recurrence and presence of symptoms were found to have a trend toward statistically significant association with negative OS outcomes (p=0.08 and p=0.10, respectively).
Our study demonstrates long-term survival for pelvic or abdominal recurrences is possible with curative salvage therapy. The presence of symptoms is a negative prognostic factor in treatment outcome and imaging may be effective for diagnosis in symptomatic and asymptomatic patients. Larger studies need to be performed to confirm these findings.
Url:
DOI: 10.1097/COC.0000000000000212
PubMed: 26237194
PubMed Central: 4733581
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003774
- to stream Pmc, to step Curation: 003773
- to stream Pmc, to step Checkpoint: 000E45
- to stream Ncbi, to step Merge: 007702
- to stream Ncbi, to step Curation: 007702
- to stream Ncbi, to step Checkpoint: 007702
- to stream Main, to step Merge: 001793
- to stream Main, to step Curation: 001791
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survival outcomes improved in contemporary cohort of patients with pelvic or abdominal recurrence after treatment for Stage I/II endometrial carcinoma</title>
<author><name sortKey="Xu, Melody J" sort="Xu, Melody J" uniqKey="Xu M" first="Melody J." last="Xu">Melody J. Xu</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chu, Christina" sort="Chu, Christina" uniqKey="Chu C" first="Christina" last="Chu">Christina Chu</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rubin, Stephen" sort="Rubin, Stephen" uniqKey="Rubin S" first="Stephen" last="Rubin">Stephen Rubin</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lin, Lilie L" sort="Lin, Lilie L" uniqKey="Lin L" first="Lilie L." last="Lin">Lilie L. Lin</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">26237194</idno>
<idno type="pmc">4733581</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733581</idno>
<idno type="RBID">PMC:4733581</idno>
<idno type="doi">10.1097/COC.0000000000000212</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">003774</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003774</idno>
<idno type="wicri:Area/Pmc/Curation">003773</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003773</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000E45</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000E45</idno>
<idno type="wicri:Area/Ncbi/Merge">007702</idno>
<idno type="wicri:Area/Ncbi/Curation">007702</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">007702</idno>
<idno type="wicri:doubleKey">0277-3732:2015:Xu M:survival:outcomes:improved</idno>
<idno type="wicri:Area/Main/Merge">001793</idno>
<idno type="wicri:Area/Main/Curation">001791</idno>
<idno type="wicri:Area/Main/Exploration">001791</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Survival outcomes improved in contemporary cohort of patients with pelvic or abdominal recurrence after treatment for Stage I/II endometrial carcinoma</title>
<author><name sortKey="Xu, Melody J" sort="Xu, Melody J" uniqKey="Xu M" first="Melody J." last="Xu">Melody J. Xu</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chu, Christina" sort="Chu, Christina" uniqKey="Chu C" first="Christina" last="Chu">Christina Chu</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rubin, Stephen" sort="Rubin, Stephen" uniqKey="Rubin S" first="Stephen" last="Rubin">Stephen Rubin</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lin, Lilie L" sort="Lin, Lilie L" uniqKey="Lin L" first="Lilie L." last="Lin">Lilie L. Lin</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">American journal of clinical oncology</title>
<idno type="ISSN">0277-3732</idno>
<idno type="eISSN">1537-453X</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Objectives</title>
<p id="P1">Pelvic and abdominal recurrences in Stage I/II endometrial carcinoma are associated with poor outcomes, yet prognostic factors for survival after recurrence are not well-described. Herein we identify patients with pelvic or abdominal recurrence after surgery for Stage I/II endometrial carcinoma and describe symptoms at presentation, prognostic factors, and salvage treatment toxicity.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">This is a retrospective cohort of 20 consecutively treated patients with recurrence after treatment for Stage I/II endometrial carcinoma followed by our Institution’s Radiation Oncology Department from 1998-2015.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">The median time to pelvic or abdominal recurrence was 18.1 months (range, 4.2-59.6 months), with 50% of recurrences at extra-nodal locations. Two year progression-free survival (PFS) was 44% and 2 year overall survival (OS) was 82%. Salvage treatments varied widely, including chemotherapy and radiation therapy (RT) (7), surgery and RT (3), and surgery, chemotherapy, and RT (3). On univariate analysis of PFS, symptoms at recurrence (p=0.04) and extra-nodal recurrences (p<0.01) were found to be statistically significant negative prognosticators for PFS. On univariate analysis of OS, increasing age at recurrence and presence of symptoms were found to have a trend toward statistically significant association with negative OS outcomes (p=0.08 and p=0.10, respectively).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">Our study demonstrates long-term survival for pelvic or abdominal recurrences is possible with curative salvage therapy. The presence of symptoms is a negative prognostic factor in treatment outcome and imaging may be effective for diagnosis in symptomatic and asymptomatic patients. Larger studies need to be performed to confirm these findings.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Xu, Melody J" sort="Xu, Melody J" uniqKey="Xu M" first="Melody J." last="Xu">Melody J. Xu</name>
</region>
<name sortKey="Chu, Christina" sort="Chu, Christina" uniqKey="Chu C" first="Christina" last="Chu">Christina Chu</name>
<name sortKey="Lin, Lilie L" sort="Lin, Lilie L" uniqKey="Lin L" first="Lilie L." last="Lin">Lilie L. Lin</name>
<name sortKey="Rubin, Stephen" sort="Rubin, Stephen" uniqKey="Rubin S" first="Stephen" last="Rubin">Stephen Rubin</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001791 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001791 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:4733581 |texte= Survival outcomes improved in contemporary cohort of patients with pelvic or abdominal recurrence after treatment for Stage I/II endometrial carcinoma }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26237194" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |